1.Malignant tumors in Russia in 2024 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2025. 278 p. (In Russ.).Злокачественные новообразования в России в 2024 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2025. 278 с.2.Prostate cancer. Clinical guidelines, 2021. Available at: https:// cr.minzdrav.gov.ru/view-cr/12_3?ysclid=mhsutk8ewi139696312 (accessed: 10.11.2025).Рак предстательной железы. Клинические рекомендации, 2021. Доступно по: https://cr.minzdrav.gov.ru/view-cr/12_3?ysclid= mhsutk8ewi139696312 (дата обращения: 10.11.2025).3.Resolution of the Panel of Experts on “The current approaches to drug therapy in patients with metastatic castration-sensitive prostate cancer”. Onkourologiya = Cancer Urology 2023;19(1): 178–84. (In Russ.). DOI: 10.17650/1726-9776-2023-19-1-178-184Резолюция по итогам Совета экспертов на тему «Современные подходы к лекарственной терапии пациентов с метастатическим гормоночувствительным раком предстательной железы». Онкоурология 2023;19(1):178–84. DOI: 10.17650/1726-9776-2023-19-1-178-1844.Nosov D.A., Volkova M.I., Gladkov O.A. et al. Prostate cancer. RUSSCO practical recommendations, part 1.2. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2):242–66. (In Russ.).Носов Д.А., Волкова М.И., Гладков О.А. и др. Рак предстательной железы. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли 2024;14(3s2):242–66.5.NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2.2026. National Comprehensive Cancer Network. 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed: 10.11.2025).6.Horwich A., Parker C., Bangma C. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(9):1119–33.7.Fizazi K., Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol 2023;34(6)1–7.8.Cornford P., Tilki D. van den Bergh R.C.N. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2024. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf (accessed: 15.07.2024).9.Shore N., Zurth C., Fricke R. et al. Evaluation of clinically relevant drug–drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration resistant prostate cancer: results of pre specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol 2019;14:527–39. DOI: 10.1007/s11523-019-00674-010.Pajouhesh H., Lenz G. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005;2(4):541–53. DOI: 10.1602/neurorx.2.4.54111.Resolution of the Expert Council “Current approaches to pharmacotherapy of non-metastatic castration-resistant prostate cancer”. Onkourologiya = Cancer Urology 2020;16(4):220–3. (In Russ.). DOI: 10.17650/1726-9776-2020-16-4-220-223Резолюция по итогам Совета экспертов на тему «Современные подходы к лекарственной терапии пациентов с неметастатическим кастрационно-резистентным раком предстательной железы». Онкоурология 2020;16(4):220–3. DOI: 10.17650/1726-9776-2020-16-4-220-22312.Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46. DOI: 10.1056/NEJMoa150374713.Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–60. DOI: 10.1056/NEJMoa170417414.Drudge-Coates L., Oh W.K., Tombal B. et al. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey. Clin Genitourin Cancer 2018;16:e411–9. DOI: 10.1016/j.clgc.2017.09.01515.Al-Batran S.E., Hozaeel W., Tauchert F.K. et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 2015;26(6):1244–8. DOI: 10.1093/annonc/mdv12916.Parker C., Zhan L., Cislo P. et al. Effect of radium-223 dichloride (Ra-223) on hospitalization: an analysis from phase 3 randomized Alpharadin in symptomatic prostate cancer patients (ALSYMPCA) trial. Eur J Cancer 2017; 71:1–6. DOI: 10.1016/j.ejca.2016.10.02017.Moilanen A., Riikonen R., Oksala R. et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Scic Rep 2015;5(1):12007. DOI: 10.1038/srep1200718.Smith M., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Eng J Med 2022;386(12):1132–42. DOI: 10.1056/NEJMoa211911519.Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. DOI: 10.1056/NEJMoa1815671. Erratum in: N Engl J Med 2022;387(9):860. DOI: 10.1056/NEJMx22000720.General characteristics of the medicinal product Nubeka®. LP No. (007078)-(РГ-RU). Current version of the instructions from 01.10.2024.Общая характеристика лекарственного препарата Нубека®. ЛП №(007078)-(РГ-RU). Актуальная версия инструкции от 01.10.2024.21.Saad F., Vjaters E., Shore N. et al.; ARANOTE Study Investigators. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024;42(36):4271–81. DOI: 10.1200/JCO-24-01798